RecruitingNCT07003997
JAK signaling and inflammation in major depression
About this title
Read the official source — NCT07003997Medication studyAges 25–55United States
Understand this study
Who could participate?
This study is for people with depression. Listed age limits: 25 years to 55 years. Other eligibility criteria apply.
What will I do during this study?
Participants are randomly assigned to daily baricitinib or placebo (an inactive comparison treatment) for eight weeks. The study includes at least eight visits over two to three months, with blood tests, symptom assessments, brain scans and computerized tests. The baricitinib dose may be adjusted at week four for participants who have not responded, if tolerated.
- Listed locations
- AtlantaSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: September 3, 2025
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 100
- Sponsor
- Emory University
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 25 Years to 55 Years
- Official registry ID
- NCT07003997
- Official title
Show the full official title
Janus Kinase (JAK) Signaling in Depression
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Atlanta
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Emory University, a university.
Does this study involve medication?
Yes. The study involves medication, including Baricitinib and Placebo.
Who can participate?
This study is for people with depression. Listed age limits: 25 years to 55 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as recruiting.
